Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis

Slide: 30 of 37

Potential Harms of rhGH Treatment to Patients with CF: Cancer Risk (3)

rhGH-treated patients with CF exhibited increases in IGF-I that were >100 ng/mL. The significance of this result for long-term risk after withdrawal of rhGH is unknown, however, and the level of evidence is insufficient to formulate a summary effect. IGFBP-3 levels were reported to increase during rhGH treatment as well, but only to levels far below the 1,000 ng/mL concentration thought to  have significance for cancer risk.

There is insufficient evidence about cancer incidence among patients who do not have CF but have been treated with rhGH for the FDA-approved conditions of growth-hormone deficiency and idiopathic short stature to evaluate risk for patients with CF.